Year: 2020

Encouraging signals of activity in difficult-to-treat tumors observed in both ongoing trials with BXCL701 and pembrolizumab (KEYTRUDA®)NEW HAVEN, Conn., Nov. 09, 2020 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced that two posters on BXCL701, the Company’s investigational, oral innate immunity activator, will be presented at the Society for Immunotherapy of Cancer’s (“SITC”) 35th Anniversary Annual Meeting being held from Monday, November 9, 2020 to Saturday, November 14, 2020.“We, along with our collaborator MD Anderson, are pleased to be presenting safety and initial efficacy data from the Phase 1b/2 trial in advanced prostate...

Completed Dosing of Fourth Cohort in RTX-240 Phase 1/2 Solid Tumor Clinical TrialDosed First Patient in RTX-240 Phase 1 Relapsed/RefractoryAcute Myeloid Leukemia Clinical TrialFiled Investigational New Drug Application with U.S. Food and Drug Administration for RTX-321 forHuman Papillomavirus 16-Positive Cancers with Frozen Drug SubstanceCAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) — Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today reported third quarter 2020 financial results and provided an overview of operational progress.“Rubius Therapeutics continues to demonstrate strong execution across our pipeline of Red Cell Therapeutics for the treatment of cancer....

Topline data remain as previously reportedPost-hoc analyses showed lenabasum treatment was associated with a benefit in lung function (forced vital capacity) in subjects on established background immunosuppressant therapies (greater than 2 years)Focusing on forced vital capacity in patients on established immunosuppressant therapies could address a key unmet need and represents a potential commercial opportunitySystemic sclerosis is a rare, life-threatening autoimmune disease affecting up to 75K AmericansNorwood, MA, Nov. 09, 2020 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today presented additional data from the RESOLVE-1 Phase 3 study of lenabasum for the...

State-of-the-art facility to be located in Bedford, MassachusettsNOVATO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare genetic diseases, today announced that it plans to build a new large-scale gene therapy manufacturing facility in Bedford, Massachusetts. The new facility will enable in-house manufacturing of the Company’s pipeline of clinical stage adeno-associated virus (AAV)- based gene therapies, including DTX301 for ornithine transcarbamylase (OTC) deficiency, DTX401 for glycogen storage disease type Ia (GSDIa), and UX701 for Wilson disease, as well as other preclinical programs. The company will continue to leverage some contract manufacturing organizations in addition...

Data to be presented in a poster and an oral session “Hot Topic Symposium: COVID-19 and Cancer” at SITCData shows CPI-006 provided enhanced and prolonged polyclonal humoral immunity to SARS–CoV–2Plans to initiate pivotal, randomized, double blind trial in December with results expected mid–2021Hosting R&D Symposium webcast on Thursday, November 12 to highlight COVID-19 program and provide updates on its cancer programsBURLINGAME, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it has completed patient enrollment in its Phase 1 study investigating the potential for CPI-006 to provide a novel immunotherapy approach for hospitalized patients with COVID-19. This novel immunotherapy may provide a therapeutic benefit...

BALA CYNWYD, Pa., Nov. 09, 2020 (GLOBE NEWSWIRE) — Global Indemnity Group, LLC (NASDAQ:GBLI) (the “Company”) today reported a net loss of $22.2 million for the nine months ended September 30, 2020 compared to net income of $41.0 million for the corresponding period in 2019. Adjusted operating income was $16.8 million for the nine months ended September 30, 2020 compared to $31.7 million for the corresponding period in 2019.Selected Operating and Balance Sheet Information(Dollars in millions, except per share data)Selected Financial Data for the Three Months Ended September 30, 2020:Underwriting income / (loss) – ($9.5) million in 2020 mainly due to catastrophes compared to $6.6 million in 2019.Investment Income – $11.7 million in 2020 compared to $11.3 million in 2019. In 2020 lower yields on fixed income were offset by improved...

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) — Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced a preclinical update on NKX019, its investigational allogeneic cancer immunotherapy that uses donor-derived natural killer (NK) cells engineered with a membrane-bound form of IL15 and a chimeric antigen receptor (CAR) targeting the CD19 antigen.The data were presented today in a poster at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting entitled “Preclinical evaluation of NKX019, a CD19-targeting CAR NK Cell”. Poster # 127.Cryopreserved NKX019 demonstrated potent, targeted anti-tumor activity in vitro and in vivo across different CD19-expressing cancer models for B cell lymphoma...

— Agonist anti-CD40 mAb CDX-1140 demonstrates best-in-class potential; additional expansion cohorts initiated––Axl and CDX-527 programs highlighted–HAMPTON, N.J., Nov. 09, 2020 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data from multiple presentations at the Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020). An interim update from the Company’s ongoing Phase 1 study of its CD40 agonist antibody, CDX-1140, and preclinical data from its AXL discovery program were presented at the meeting. In addition, the Phase 1 study design for the Company’s bispecific candidate, CDX-527, which couples CD27 co-stimulation with blockade of the PD-L1/PD-1 pathway, were also presented in a clinical trial in progress poster.“CDX-1140...

Boston, MA, Nov. 09, 2020 (GLOBE NEWSWIRE) — Duck Creek Technologies, Inc. (Nasdaq: DCT) (“Duck Creek”), a provider of SaaS-delivered enterprise software to the property & casualty (“P&C”) insurance industry, announced today that certain of its stockholders have commenced an underwritten public offering of 8,000,000 shares of Duck Creek’s common stock. Additionally, the selling stockholders expect to grant the underwriters a 30-day option to purchase up to 1,200,000 additional shares of Duck Creek’s common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.Duck Creek is not selling any shares in the offering and will not receive any of the proceeds from the sale.J.P. Morgan, Goldman Sachs & Co. LLC and BofA Securities are serving...

For første gang i Danmark er der blevet rejst et robotfremstillet træbyggeri til almindelig beboelse. Det er lykkedes i kraft af et unikt samarbejde mellem Odico A/S, BRAV ApS, CS Byggefirma ApS samt bygherre Dennis Kassentoft Nielsen.Rejsegildet fandt sted fredag eftermiddag i Odense, hvor byggeriet er blevet anlagt.Samarbejdet har resulteret i et byggesæt, hvor konstruktionen blev udført og færdiggjort væsentligt hurtigere og mere præcist end ved konventionelt byggeri.Formålet med det udviklede koncept er at effektivisere fremstilling af trækonstruktioner, og den nye metode muliggør, at teknologi og menneske taler sammen på en ny måde. Det medfører et mere effektivt og bæredygtigt træbyggeri.En af de udfordringer, der kan være ved digital fremstilling, er at konvertere data mellem afsender og modtager. Her har Odico og BRAV udviklet...